Final results of the international, expanded-access program of everolimus in patients with advanced renal cell carcinoma who progress after prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy.

Castellano, D. E.; Bodrogi, I.; Booth, J. L.; Rosamilia, M.; Yuan, R. R.; Hawkins, R.; Knox, J. J.; Blank, C. U.; Gruenwald, V.; Karakiewicz, P. I.; Bavbek, S. E.; Miller, K.; Machiels, J. H.; Lee, S.; Larkin, J. M. G.; Bono, P.; Rha, S. Y.

dc.contributor.author	Castellano, D. E.
dc.contributor.author	Bodrogi, I.
dc.contributor.author	Booth, J. L.
dc.contributor.author	Rosamilia, M.
dc.contributor.author	Yuan, R. R.
dc.contributor.author	Hawkins, R.
dc.contributor.author	Knox, J. J.
dc.contributor.author	Blank, C. U.
dc.contributor.author	Gruenwald, V.
dc.contributor.author	Karakiewicz, P. I.
dc.contributor.author	Bavbek, S. E.
dc.contributor.author	Miller, K.
dc.contributor.author	Machiels, J. H.
dc.contributor.author	Lee, S.
dc.contributor.author	Larkin, J. M. G.
dc.contributor.author	Bono, P.
dc.contributor.author	Rha, S. Y.
dc.date.accessioned	2021-03-05T09:21:16Z
dc.date.available	2021-03-05T09:21:16Z
dc.date.issued	2011
dc.identifier.citation	Gruenwald V., Karakiewicz P. I. , Bavbek S. E. , Miller K., Machiels J. H. , Lee S., Larkin J. M. G. , Bono P., Rha S. Y. , Castellano D. E. , et al., "Final results of the international, expanded-access program of everolimus in patients with advanced renal cell carcinoma who progress after prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy.", JOURNAL OF CLINICAL ONCOLOGY, cilt.29, 2011
dc.identifier.issn	0732-183X
dc.identifier.other	av_9d799c20-19b8-4a8a-bcbc-e2710e55158c
dc.identifier.other	vv_1032021
dc.identifier.uri	http://hdl.handle.net/20.500.12627/105800
dc.language.iso	eng
dc.subject	Tıp
dc.subject	Sağlık Bilimleri
dc.subject	Dahili Tıp Bilimleri
dc.subject	İç Hastalıkları
dc.subject	Onkoloji
dc.subject	Klinik Tıp (MED)
dc.subject	ONKOLOJİ
dc.subject	Klinik Tıp
dc.title	Final results of the international, expanded-access program of everolimus in patients with advanced renal cell carcinoma who progress after prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy.
dc.type	Makale
dc.relation.journal	JOURNAL OF CLINICAL ONCOLOGY
dc.contributor.department	, ,
dc.identifier.volume	29
dc.identifier.issue	15
dc.contributor.firstauthorID	200541

Files in this item

Files	Size	Format	View
There are no files associated with this item.

This item appears in the following Collection(s)

Makale [92796]

Show simple item record